DLA Piper Advised Marinomed On Sale Of Carragelose Business To Unither Pharmaceuticals
DLA Piper Advised Marinomed On Sale Of Carragelose Business To Unither Pharmaceuticals
The blocker forms a protective layer on mucosal surfaces, preventing viruses and allergens from interacting
Prestigious law firm DLA Piper has counseled Marinomed Biotech AG, a leading Austrian biotechnology business, on the sale of its Carragelose business to Unither Pharmaceuticals, a French contract development and manufacturing organization.
Marinomed Biotech is a science-based biotech company with a growing development pipeline. It develops innovative patent-protected products based on the Marinosolv® platform.
The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and develops new therapeutics for autoreactive immune disorders.
Headquartered in Korneuburg, Austria, the company is listed on the Vienna Stock Exchange.
Carregelose is a sulphated polymer from red seaweed and a unique, broadly active virus and allergen-blocking compound.
The multi-disciplinary team from DLA Piper's Vienna office was led by Corporate Partner Maria Doralt.
The team comprised partners Sabine Fehringer (IPT), Christian Temmel (Corporate), Marc Lager (Lit&Reg), Dimitar Hristov (Tax), and Stephan Nitzl.
They were supported by counsel Christian Knauder-Sima, senior associate Eric Wingert, and junior associates Christian Scheucher and Madeleine Albers.
Others in the team included Maria Doralt, Sabine Fehringer, Christian Temmel, Christian Knauder-Sima, Stephan Nitzl, Dimitar Hristov, Madeleine Albers, Eric Wingert and Christian Scheucher.
Click to know more about DLA Piper
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.
